Proposed Collection; Requesting Comments on Notice 2021-57

CourtInternal Revenue Service,Treasury Department
Citation86 FR 74430
Publication Date30 December 2021
Record Number2021-28372
Federal Register / Vol. 86, No. 248 / Thursday, December 30, 2021 / Notices
New Jersey Avenue SE, Room PL–401,
Washington, DC 20590–0001.
Instructions: All submissions must
include the agency name and docket
Jordan Katz, Community Planner, U.S.
DOT Volpe Center, Telephone (617)
494–3783 or email
: 49 U.S.C.
Section 6503 requires that the Secretary
of Transportation develop a 5-year
transportation research and
development strategic plan to guide
future Federal transportation research
and development activities. The statute
states that the strategic plan shall
describe how the plan furthers the
primary purpose of the transportation
research and development program.
49 U.S.C. Chapter 65 outlines the
following primary purposes of
transportation research:
Promoting safety
Improving mobility of people and
Reducing congestion
Improving the durability and
extending the life of transportation
Preserving the existing
transportation system
Preserving the environment
Reducing transportation
cybersecurity risks
DOT is in the process of updating its
strategic plan for FY 2022–2026 and
released a Draft Strategic Framework in
December 2021, which outlined the
following six draft DOT Strategic Goals:
Economic strength and global
Climate and sustainability
Organizational excellence
The Draft Strategic Framework can be
accessed at https://
In order to align its research strategy
and programs with the Department’s
goals, DOT is developing a new
Research, Development, and
Technology (RD&T) Strategic Plan for
OST–R invites the public to provide
comments to inform the development of
the 5-year strategic plan for
transportation RD&T. Comments should
regard appropriate RD&T activities to
meet the purposes and considerations
listed above and/or emerging RD&T
challenges, opportunities, and priorities
that DOT RD&T should address over the
next five years. In particular, comments
may respond to any or all of the
following questions:
1. How should DOT prioritize and
invest in research activities over the
next five years? Over the next 30 years?
2. What types of research activities
should DOT undertake to meet its
strategic goals?
3. What key social, demographic,
economic, technological, and/or other
trends influence transportation today
and into the future?
4. What emerging challenges or
opportunities or knowledge gaps in
transportation warrant additional
Federal RD&T activities or investments?
5. How can DOT best lead and
coordinate its RD&T activities with
Federal, State, local, tribal, private
sector, non-profit institutions, and
international partners?
6. What activities should DOT adopt
to facilitate deployment of DOT research
results into the U.S. transportation
7. Is there anything else you want to
share or say regarding DOT’s research
portfolio and activities?
Issued on December 23, 2021.
Jordan Wainer Katz,
Community Planner.
[FR Doc. 2021–28283 Filed 12–29–21; 8:45 am]
Internal Revenue Service
Proposed Collection; Requesting
Comments on Notice 2021–57
: Internal Revenue Service (IRS),
: Notice and request for
: The Internal Revenue Service,
as part of its continuing effort to reduce
paperwork and respondent burden,
invites the general public and other
federal agencies to take this opportunity
to comment on proposed and/or
continuing information collections, as
required by the Paperwork Reduction
Act of 1995. The IRS is soliciting
comments concerning Notice 2021–57,
Funding relief for multiemployer
defined benefit pension plans under the
American Rescue Plan Act of 2021.
: Written comments should be
received on or before February 28, 2022
to be assured of consideration.
: Direct all written comments
to Andres Garcia, Internal Revenue
Service, Room 6526, 1111 Constitution
Avenue NW, Washington, DC 20224.
You must reference the information
collection’s title, form number,
reporting or record-keeping requirement
number, and OMB number in your
Requests for additional information or
copies of the notice should be directed
to Jon Callahan, (737) 800–7639, at
Internal Revenue Service, Room 6526,
1111 Constitution Avenue NW,
Washington, DC 20224, or through the
internet at
The IRS is currently seeking
comments concerning the following
information collection tools, reporting,
and record-keeping requirements:
Title: Funding relief for
multiemployer defined benefit pension
plans under the American Rescue Plan
Act of 2021.
OMB Number: 1545–2300.
Notice Number: 2021–57.
Abstract: The American Rescue Plan
Act of 2021 (ARP), P.L. 117–2, sections
9701, 9702, and 9703 provide elective
funding relief for multiemployer
defined benefit pension plans to address
the continued impact of COVID–19.
This notice provides guidance for
sponsors of multiemployer defined
benefit pension plans on the elections
under sections 9701 and 9702 of the
ARP Act, and the relief provided under
section 9703 of the ARP Act, relating to
Internal Revenue Code (IRC) sections
431 and 432.
Current Actions: There is no change to
the existing collection.
Type of Review: Extension of a
currently approved collection.
Affected Public: Business or other for-
profit organizations, and not-for-profit
Estimated Number of Responses: 937.
Estimated Time per Respondent: 58
Estimated Total Annual Burden
Hours: 896.
The following paragraph applies to all
of the collections of information covered
by this notice:
An agency may not conduct or
sponsor, and a person is not required to
respond to, a collection of information
unless the collection of information
displays a valid OMB control number.
Books or records relating to a collection
of information must be retained as long
as their contents may become material
in the administration of any internal
revenue law. Generally, tax returns and
tax return information are confidential,
as required by 26 U.S.C. 6103.
Request for comments: Comments
submitted in response to this notice will
be summarized and/or included in the
request for OMB approval. All
comments will become a matter of
public record. Comments are invited on:
VerDate Sep<11>2014 17:19 Dec 29, 2021 Jkt 256001 PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 E:\FR\FM\30DEN1.SGM 30DEN1
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 86, No. 248 / Thursday, December 30, 2021 / Notices
(a) Whether the collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the collection of
information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; (d) ways to
minimize the burden of the collection of
information on respondents, including
through the use of automated collection
techniques or other forms of information
technology; and (e) estimates of capital
or start-up costs and costs of operation,
maintenance, and purchase of services
to provide information.
Approved: December 27, 2021.
Jon R. Callahan,
Tax Analyst.
[FR Doc. 2021–28372 Filed 12–29–21; 8:45 am]
Tiered Pharmacy Copayments for
Medications; Calendar Year 2022
: Department of Veterans Affairs.
: Notice.
: This Department of Veterans
Affairs (VA) notice updates the
information on Tier 1 medications.
: Mr.
Joseph Duran, Director of Policy and
Planning, Office of Community Care
(13BOA1), Veterans Health
Administration, 3773 Cherry Creek
North Drive, Denver, CO 80209, 303–
370–1637. This is not a toll-free
telephone number.
: Section
17.110 of title 38, CFR, governs
copayments for medications that VA
provides to Veterans. Section 17.110
provides the methodologies for
establishing the copayment amount for
each 30-day or fewer supply of
medication provided by VA on an
outpatient basis (other than medication
administered during treatment).
Tier 1 medication means a multi-
source medication that has been
identified using the process described in
paragraph (b)(2) of this section. Not less
than once per year, VA will identify a
subset of multi-source medications as
Tier 1 medications. Only medications
that meet all of the criteria in 38 CFR
17.110(b)(2)(i), (ii) and (iii) will be
eligible to be considered Tier 1
medications, and only those
medications that meet all of the criteria
in paragraph (b)(2)(i) of this section will
be assessed using the criteria in
paragraphs (b)(2)(ii) and (iii).
Based on the methodologies set forth
in § 17.110, this notice updates the list
of Tier 1 medications for Calendar Year
2022. The Tier 1 medication list is
posted on VA’s Community Care
website at the following link: https://
revenue_ops/copays.asp under the
heading ‘‘Tier 1 Copay Medication
The following table is the Tier 1
Copay Medication List that is effective
January 1, 2022, and will remain in
effect until December 31, 2022.
Condition VA product name
Arthritis and Pain ................................................. Aspirin Buffered Tablet.
Aspirin Chewable Tablet.
Aspirin Enteric-Coated (EC) Tablet.
Allopurinol Tablet.
Celecoxib Capsule.
Diclofenac Tablet.
Ibuprofen Tablet.
Meloxicam Tablet.
Naproxen Tablet.
Blood Thinners and .............................................
Platelet Inhibitors ................................................. Clopidogrel Bisulfate Tablet.
Warfarin Sodium Tablet.
Cholesterol .......................................................... Atorvastatin Tablet.
Ezetimibe Tablet.
Pravastatin Tablet.
Rosuvastatin Calcium tablet.
Simvastatin Tablet.
Dementia ............................................................. Donepezil Tablet.
Diabetes .............................................................. Glimepiride Tablet.
Glipizide Tablet.
Metformin Hydrochloride (HCL) Tablet.
Metformin HCL 24-Hour Sustained Action (SA) Tablet.
Pioglitazone HCL Tablet.
Electrolyte Supplement ....................................... Potassium SA Tablet.
Potassium SA Dispersible Tablet.
Gastrointestinal Health ........................................ Famotidine Tablet.
Omeprazole EC Capsule.
Pantoprazole Sodium EC Capsule.
Psyllium Mucilloid.
Glaucoma and Eye Care ..................................... Diclofenac Solution.
Dorzolamide 2%/Timolol 0.5% Solution.
Latanoprost 0.005% Solution.
Carboxymethylcellulose Sodium Solution.
Heart Health and Blood Pressure ....................... Amlodipine Tablet. Aspirin (see Arthritis & Pain).
Atenolol Tablet.
Carvedilol Tablet.
Chlorthalidone Tablet.
Clonidine Tablet.
Digoxin Tablet.
Diltiazem 24-Hour Capsule.
Diltiazem HCL Tablet.
VerDate Sep<11>2014 17:19 Dec 29, 2021 Jkt 256001 PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 E:\FR\FM\30DEN1.SGM 30DEN1
khammond on DSKJM1Z7X2PROD with NOTICES

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT